Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy
The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during transradial hepatic arterial infusion chemotherapy (HAIC) can diminish the incidence of radial artery occlusion (RAO) post-procedure
- EligibilityCriteria: Inclusion Criteria:  Signed informed consent; Age: 18-69 years; Pathologically diagnosed with hepatocellular carcinoma or clinically in accordance with the American Association for the Study of Liver Diseases (AASLD) diagnostic criteria for hepatocellular carcinoma; Clinical stage: BCLC stage B or C, liver function Child-Pugh class A or B$ (≤7 points)$, ECOG $score <2$; suitable for HAIC treatment; Adequate hematological and organ function, i.e., based on laboratory results obtained within 7 days before treatment, such as complete blood count, liver and kidney function, coagulation function, myocardial enzymes, etc., to assess whether the patient is suitable for HAIC treatment; Low-risk patients for VTE (Venous Thromboembolism) according to the Padua scoring system (≤3 points).  Exclusion Criteria:  Concomitant primary tumors of other organs or histologically diagnosed tumors inconsistent with hepatocellular carcinoma; Serious diseases of the heart, lungs, kidneys, or other organs; Patients who have received trans-radial interventional surgery within the past 3 months; Patients with thrombocytopenia $and/or $leukopenia due to cirrhosis-related coagulation disorders or splenic hyperfunction are excluded; Preoperative radial artery ultrasound suggests vascular anatomical abnormalities, malformations, etc., unsuitable for trans-radial interventional treatment; Patients with thrombotic diseases who are undergoing anticoagulation therapy; Any unstable conditions or situations that may jeopardize the patient's safety or their compliance with the study; Pregnant and lactating women. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 69 Years - StdAgeList: Adult, Older Adult